BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer

BridgeBio Pharma (NASDAQ:BBIO) had its target price raised by equities research analysts at Oppenheimer from $81.00 to $83.00 in a report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 7.54% from the company’s previous close.

Several other equities analysts have also recently weighed in on BBIO. Piper Sandler lifted their price target on BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. The Goldman Sachs Group upped their price target on BridgeBio Pharma from $55.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. JPMorgan Chase & Co. raised their price objective on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Truist Financial boosted their price objective on shares of BridgeBio Pharma from $80.00 to $86.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Twenty-two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $81.55.

BridgeBio Pharma Trading Up 1.5%

Shares of NASDAQ:BBIO traded up $1.12 during mid-day trading on Friday, reaching $77.18. The company had a trading volume of 779,416 shares, compared to its average volume of 3,200,896. BridgeBio Pharma has a one year low of $28.33 and a one year high of $84.94. The company’s 50-day moving average price is $75.57 and its 200-day moving average price is $62.88. The firm has a market cap of $14.87 billion, a price-to-earnings ratio of -18.46 and a beta of 1.13.

Insider Activity at BridgeBio Pharma

In related news, Director Andrew Lo sold 55,000 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $65.69, for a total value of $3,612,950.00. Following the completion of the sale, the director owned 50,583 shares of the company’s stock, valued at $3,322,797.27. This trade represents a 52.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $74.40, for a total transaction of $2,976,000.00. Following the completion of the sale, the chief executive officer directly owned 775,686 shares of the company’s stock, valued at approximately $57,711,038.40. This represents a 4.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 300,700 shares of company stock worth $21,034,671 over the last 90 days. 18.20% of the stock is owned by insiders.

Institutional Trading of BridgeBio Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vontobel Holding Ltd. raised its stake in shares of BridgeBio Pharma by 82.6% in the fourth quarter. Vontobel Holding Ltd. now owns 19,062 shares of the company’s stock worth $1,458,000 after purchasing an additional 8,620 shares during the last quarter. Y Intercept Hong Kong Ltd increased its holdings in BridgeBio Pharma by 288.4% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 54,110 shares of the company’s stock worth $4,139,000 after buying an additional 40,179 shares in the last quarter. Rhenman & Partners Asset Management AB bought a new stake in BridgeBio Pharma in the 4th quarter worth about $6,242,000. Federation des caisses Desjardins du Quebec raised its position in BridgeBio Pharma by 17.5% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 9,529 shares of the company’s stock worth $729,000 after buying an additional 1,421 shares during the last quarter. Finally, Brooklyn Investment Group bought a new position in BridgeBio Pharma during the 4th quarter valued at about $315,000. 99.85% of the stock is currently owned by institutional investors.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 Phase 3 topline: study met primary endpoint (annualized height velocity) with a mean treatment difference vs. placebo of +2.10 cm/yr (LS mean +1.74 cm/yr); key secondary endpoints and a favorable safety read support regulatory filings planned for H2 2026. Read More.
• Positive Sentiment: Analyst and market reaction: outlets and analysts called the data “compelling,” driving buying interest and upward analyst sentiment/price targets. Read More.
• Positive Sentiment: Competitive positioning: BridgeBio’s results pressured rival programs (reports show BioMarin and Ascendis shares fell), indicating potential market-share implications if infigratinib advances to approval. Read More.
• Neutral Sentiment: Short-interest reports in feeds show zero shares outstanding (likely a data glitch or reporting lag) — not meaningful for positioning right now.
• Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M), which some investors interpret negatively despite management’s large remaining stake. Read More.
• Negative Sentiment: Near-term financials: Zacks flagged BridgeBio as likely to report negative earnings for the upcoming quarter — the company remains a clinical-stage biotech with ongoing cash burn and execution risk despite the clinical win. Read More.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.